Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $28.5852W HIGH $77.00
Volume
42.59 K
Value Traded
8.07 M
Short % Float
11.45%
Days to Cover
5.0
-1.25%Week
-12.03%1 Month
+8.74%3 Month
+22.86%6 Month
+80.76%5 Year
+293.92%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
199.17 M
EPS (TTM)
4.23
P/E Ratio
14.58
Ent. Value
207.18 M
Total Shares
3.23 M
Float Shares
2.06 M
Insiders
36.36%
Institutions
32.13%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
PDEX Catalyst Timeline
Dated clinical, regulatory and corporate events for Pro-Dex, Inc.
Past FDA Catalysts and PDUFA Decisions
How PDEX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Pro-Dex, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every PDEX program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Van Kirk Richard Lee JrDirector, Officer (Chief Executive Officer) | Sell | -290 79,703 held | $58.94 | 09/11/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in PDEX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in PDEX for Q2 2026. | ||||
PDEX Institutional Ownership Trends
PDEX Short Interest
Shares sold short, counted twice a month.
11.45%
Short % of Float
of tradable shares sold short
235.9K
Shares Sold Short
+18.3% vs prior count
5.0 Moderate
Days to Cover
trading days of normal volume to buy every short share back
47.7K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PDEX ranks across every disease it competes in
Competitive Position is a premium feature
See how PDEX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPDEX News
PDEX▲ +0.5%today
Pro-Dex, Inc. Announces Fiscal 2027 First Quarter Results
Pro-Dex, Inc. reported its fiscal 2027 first quarter results, showing a net sales increase of 11% to $20.6 million. Gross profit rose by 28%, while operating income increased by 13%. However, net income fell to $3.0 million, impacted by unrealized gains on investments. The company remains optimistic about future growth.
Read more →PDEXPro-Dex, Inc. Announces Fiscal 2026 Fourth Quarter and Full-Year Results
Pro-Dex, Inc. reported strong financial results for its fiscal 2026 fourth quarter and full year, with a 17% increase in net sales and a 103% rise in gross profit compared to the previous year. The company's acquisition of Advanced Precision Machining contributed positively to revenue growth. However, operating expenses also increased significantly, which could pose challenges moving forward.
Read more →PDEXPRO-DEX, INC. ANNOUNCES FISCAL 2026 THIRD QUARTER AND NINE-MONTH RESULTS
Pro-Dex, Inc. reported its fiscal 2026 third quarter financial results, revealing a 15% increase in sales, totaling $19.9 million, driven largely by increased shipments of its orthopedic handpiece. The company's net income for the quarter rose to $3.9 million, reflecting a gain attributed to contingent value rights from Monogram Technologies. However, the report also highlighted a decline in gross margin, and operating expenses increased significantly due to the recent acquisition of Advanced Precision Machining, contributing to higher general and administrative costs. Overall, while sales and income showed positive growth, concerns over lowered margins and increased operating expenses were noted.
Read more →PDEXPRO-DEX, INC. ANNOUNCES ACQUISITION OF ADVANCED PRECISION MACHINING
Pro-Dex, Inc. announced the acquisition of Advanced Precision Machining LLC on February 9, 2026. APM, known for manufacturing machined sub-assemblies and parts for aerospace and defense, will operate independently under Pro-Dex. CEO Rick Van Kirk expressed enthusiasm about integrating APM's automation and technology to enhance Pro-Dex's production capabilities. The acquisition aligns with Pro-Dex's expansion strategy following a recent contract extension with its largest customer.
Read more →PDEXPRO-DEX, INC. ANNOUNCES FISCAL 2026 SECOND QUARTER AND SIX-MONTH RESULTS
Pro-Dex, Inc. reported its fiscal 2026 second quarter results, highlighting a significant growth in sales and net income compared to the previous year. For the three months ended December 31, 2025, the company's sales rose by 11% to $18.7 million, while net income reached $2.2 million. Despite improvements in sales and operating income, the company experienced a slight decrease in gross margin and has seen reduced repair revenue from legacy products. Pro-Dex also announced plans for an acquisition that may enhance capacity and manufacturing technology.
Read more →PDEX▼ -8.3%on this news
PRO-DEX, INC. ANNOUNCES CONTRACT EXTENSION WITH LARGEST CUSTOMER
PRO-DEX, INC. has announced a contract extension with its largest customer, now lasting until December 31, 2028. This amendment adds minimum purchase volumes for the next two calendar years. The CEO highlighted the long-standing relationship of over fifteen years, expressing commitment to delivering long-term value.
Read more →PDEXPRO-DEX, INC. ANNOUNCES FISCAL 2026 FIRST
Pro-Dex, Inc. announced its financial results for the first quarter of fiscal 2026, reporting a 24% increase in sales compared to the same period last year. Net income also rose significantly, indicating positive growth for the company. However, the gross margin has decreased due to rising costs, and operating expenses have increased as well. The company's resumption of the next-generation handpiece shipments and cash inflow from an investment in Monogram Technologies are viewed positively.
Read more →PDEXPRO-DEX, INC. ANNOUNCES FISCAL 2025 FOURTH QUARTER AND FULL-YEAR RESULTS
Pro-Dex, Inc. announced its financial results for fiscal 2025, with sales increasing by 24% to $66.6 million. Despite challenges such as reduced gross profit and operating expenses rising by 20%, operating income showed a strong growth of 49%. CEO Richard L. Van Kirk expressed optimism for fiscal 2026, pointing to a significant backlog and ongoing improvements within the company's operations.
Read more →PDEXPRO-DEX, INC. ANNOUNCES FISCAL 2025 THIRD QUARTER AND NINE-MONTH RESULTS
Pro-Dex, Inc. reported its financial results for the third quarter and nine months ended March 31, 2025. The company experienced a 22% increase in net sales compared to the same quarter last year, driven by shipments of its next-generation orthopedic handpiece. Gross profit rose significantly, supported by a favorable product mix, while operating income also saw a substantial increase. However, operating expenses increased due to higher personnel-related costs, and the company's financial performance remains heavily tied to its largest customer.
Read more →PDEXPro-Dex INC. ANNOUNCES FISCAL 2025 SECOND QUARTER
Pro-Dex, Inc. (PDEX) reported strong financial results for its fiscal 2025 second quarter, showing a 33% increase in sales to $16.8 million. The company achieved an 81% rise in net profit, amounting to $5.1 million compared to the same period in the previous fiscal year. The gross margin also improved significantly, reflecting operational efficiencies. Pro-Dex anticipates continued revenue growth in the upcoming quarters driven by production shipments of their next generation orthopedic handpiece.
Read more →PDEXPRO-DEX, INC. ANNOUNCES FISCAL 2025 FIRST QUARTER RESULTS
Pro-Dex, Inc. has reported strong financial results for its fiscal 2025 first quarter, with sales rising by 25% to $14.9 million driven by increased demand. The company achieved a net income of $2.5 million, compared to a loss of $615,000 in the previous year, attributed to improved gross profitability and operating income. While expenses rose by 17%, the favorable product mix contributed to a higher gross margin. The CEO expressed optimism regarding the shipment of the next-generation surgical handpiece this fiscal year.
Read more →PDEXPRO-DEX, INC. ANNOUNCES FISCAL 2024 FOURTH QUARTER AND FULL-YEAR RESULTS
Pro-Dex, Inc. announced positive financial results for its fiscal 2024 fourth quarter and full year, reporting a 41% increase in quarterly sales compared to the same period last year. Operating income also showed a substantial increase of 46%, attributed mainly to enhanced repair services and new unit sales to a major customer. Despite these gains, the company experienced a decline in gross margin due to price pressures, and net income for the year fell significantly largely due to unrealized losses on investments. The CEO expressed satisfaction with the company's growth trajectory and the hiring of a new Director of Operations to support ongoing expansion.
Read more →PDEXPRO-DEX, INC. ANNOUNCES FISCAL 2024 THIRD QUARTER AND NINE-MONTH RESULTS
Pro-Dex, Inc. reported its fiscal 2024 third quarter results, revealing a 9% increase in net sales to $14.3 million and a 5% rise in gross profit to $4 million compared to the previous year. Operating income also saw a modest increase of 7% to $2.2 million. However, net income declined sharply to $655,000, impacted by unrealized losses on marketable investments. The company remains optimistic about sustaining growth into the next fiscal year.
Read more →PDEXINC. ANNOUNCES FISCAL 2024 SECOND QUARTER
Pro-Dex, Inc. (PDEX) announced its fiscal 2024 second quarter financial results, showing a 12% increase in sales to $12.6 million and a 7% rise in profit to $2.8 million. Despite these gains, operating income fell by 32% due to a rise in expenses, primarily from administrative costs. Overall, while the company experienced growth in sales and profit, it reported a loss over the six-month period compared to the previous year, impacted by unrealized losses on marketable investments.
Read more →PDEX▲ +5.3%on this news
PRO-DEX, INC. ANNOUNCES FISCAL 2024 FIRST QUARTER
Pro-Dex, Inc. reported its financial results for the first quarter of fiscal 2024, revealing an 8% increase in sales to $11.9 million compared to the previous year. Despite this growth, the company experienced a net loss of $615,000, contrasting with a profit of $1.2 million in the same quarter last year. The increased sales were largely attributed to repairs of surgical handpieces sold to major customers. Operating expenses decreased by $181,000, indicating potential cost management. However, the financial report also reflected unrealized losses on investments amounting to $2.6 million.
Read more →PDEXPRO-DEX, INC. ANNOUNCES FISCAL 2023 FOURTH QUARTER AND FULL-YEAR RESULTS
Pro-Dex, Inc. has announced its financial results for the fourth quarter and full year ending June 30, 2023. While overall sales for the fiscal year increased by 10% due to strong repair revenue, the fourth quarter experienced a significant 16% decline in sales driven by decreased medical device sales. The company reported a net income of $7.1 million, reflecting substantial growth year-over-year, despite facing challenges in the fourth quarter. Management remains optimistic about future business growth, bolstered by the completion of their Franklin facility and a record backlog of orders.
Read more →PDEXINC. ANNOUNCES FISCAL 2023 THIRD QUARTER
Pro-Dex, Inc. reported strong financial results for its fiscal 2023 third quarter, with sales rising 41% to $13.1 million and net income increasing by 33% to $3.8 million. The rise in sales was primarily due to an enhanced repair program, which also contributed to an overall increase in repair revenue. However, gross profit for the nine-month period saw a decrease, attributed to rising costs and the advances made in repairs. The company's CEO expressed optimism about achieving record revenues for the fiscal year ahead.
Read more →PDEXPRO-DEX, INC. ANNOUNCES FISCAL 2023 SECOND QUARTER AND SIX-MONTH RESULTS
Pro-Dex, Inc. announced its fiscal 2023 second quarter results, revealing an 11% increase in sales year-over-year, primarily driven by orthopedic surgical handpiece sales. However, net income declined by 23%, attributed to rising repair costs and component price increases. The company aims to mitigate rising costs through improved operational efficiency and plans to commence operations at a new facility. Pro-Dex remains optimistic about its future despite these challenges.
Read more →PDEXPRO-DEX, INC. ANNOUNCES FISCAL 2023 FIRST QUARTER
Contact: Richard L. Van Kirk, Chief Executive Officer PRO-DEX, INC. ANNOUNCES FISCAL 2023 FIRST QUARTER IRVINE, CA, November 3, 2022 - PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results for its fiscal 2023 first quarter ended September 30, 2022. The Company also
Read more →PDEXPRO-DEX, INC. ANNOUNCES FISCAL 2022 FOURTH QUARTER AND FULL-YEAR RESULTS
Contact: Richard L. Van Kirk, Chief Executive Officer PRO-DEX, INC. ANNOUNCES FISCAL 2022 FOURTH QUARTER AND FULL-YEAR RESULTS CA, August 25, 2022 - PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results for its fiscal 2022 fourth quarter and full-year ended June 30
Read more →About Pro-Dex, Inc.
Headquarters2361 MCGAW AVENUE, IRVINE, CA, 92614
BIOPHARMAWATCH ELITE PLUS
Trade the next PDEX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime